Riedl, J; Posch, F; Prager, G; Eisterer, W; Ohler, L; Thamer, S; Wilthoner, K; Petzer, A; Pichler, P; Hubmann, E; Winder, T; Burgstaller, S; Korger, M; Andel, J; Greil, R; Pecherstorfer, M; Philipp-Abbrederis, K; Djanani, A; Gruenberger, B; Langle, F; Woll, E; Gerger, A.
The AST/ALT (De Ritis) ratio predicts clinical outcome in pancreatic cancer patients treated with first-line nab-paclitaxel and gemcitabine: post-hoc analysis of an Austrian multicenter, non-interventional study
ANN ONCOL. 2019; 30: -European-Society-for-Medical-Oncology (ESMO) 21st World Congress on Gastrointestinal Cancer; JUL 03-06, 2019; Barcelona, SPAIN.
Doi: 10.1093/annonc/mdz155.285
[Poster]
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG